Quick Takeaways: Why It Matters? CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoi...
Quick Takeaways: Why It Matters? Paw Prosper’s exclusive US and Canada partnership with Elvation Medical expands its veterinary rehabilitation portfolio with the PiezoWave2T VET shockwave system, strengthening its position in both equine and small-animal markets. By c...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? CT-RevitL positions Enovis’s Companion Animal Health business to deepen its role in technology-enabled, non-drug pain and mobility management, giving clinics a more standardized, high-powered PBM platform that can turn laser therapy into a recurring, protoc...
Quick Takeaways: Why It Matters? VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia. The clinical data in aged Beagles shows a single...
Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways: Why It Matters? ALA-1000’s data support a true once-monthly, long-acting analgesic option, which could meaningfully shift osteoarthritis pain management away from daily oral medications in suitable dogs. If approved, the combination of dura...
